June 1, 2025

Meta-analysis of hydrocortisone in the treatment of severe community-acquired pneumonia.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Meta-analysis demonstrates lower mortality rates in severe community-acquired pneumonia with hydrocortisone, suggesting enhanced treatment efficacy.

Hydrocortisone treatment significantly reduced mortality in patients with severe community-acquired pneumonia.
The hydrocortisone group had a mortality rate of 6.0% compared to 14.0% in the standard treatment group, indicating effectiveness.
Meta-analysis was conducted on five randomized controlled trials involving 1,031 patients to assess outcomes and risks.
No significant increase in adverse reactions was noted, suggesting hydrocortisone's safety alongside standard treatment.

Gu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Meta-analysis demonstrates lower mortality rates in severe community-acquired pneumonia with hydrocortisone, suggesting enhanced treatment efficacy.